Literature DB >> 12377338

Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas.

Anca-Ligia Grosu1, Horst Feldmann, Susanne Dick, Brigitte Dzewas, Carsten Nieder, Hartmut Gumprecht, Andreas Frank, Markus Schwaiger, Michael Molls, Wolfgang Andreas Weber.   

Abstract

PURPOSE: Using MRI, residual tumor cannot be differentiated from nonspecific postoperative changes in patients with brain gliomas after surgical resection. The goal of this study was to analyze the value of 123I-alpha-methyl-tyrosine-single photon emission CT (IMT-SPECT) in radiotherapy planning of patients with brain gliomas after surgical resection. METHODS AND MATERIALS: In 66 patients with surgically resected brain gliomas (33 glioblastomas, 20 anaplastic astrocytomas, 7 anaplastic oligodendrogliomas, and 6 low-grade astrocytomas), IMT-SPECT and MRI were performed for radiotherapy planning. On the MRI/IMT-SPECT fusion images, the volume with IMT uptake was compared with the volume of the hyperintensity areas of T(2)-weighted MRI and with the volume of contrast enhancement on T(1)-weighted MRI. The regions with IMT uptake and/or MRI changes (composite Vol-MRI/IMT), regions with overlay of IMT uptake and MRI changes (common Vol-MRI/IMT), area with IMT uptake without MRI changes (increase Vol-MRI/IMT), and area with only MRI changes (Vol-MRI minus IMT) were analyzed separately. The planning target volume and boost volume defined using MRI information alone was compared with the planning target volume and boost volume defined by also using the SPECT information.
RESULTS: Focally increased IMT uptake was observed in 25 (38%) of 66 patients, contrast enhancement on MRI was outlined in 59 (89%) of 66 patients, and hyperintensity areas on T(2)-weighted MRI were found in all 66 investigated patients. The mean composite Vol-T(2)/IMT was 73 cm(3). The relative increase Vol-T(2)/IMT, mean relative common Vol-T(2)/IMT, and mean relative Vol-T(2) minus IMT was 4%, 6%, and 90% of the composite Vol-T(2)/IMT, respectively. The mean composite Vol-T(1)/IMT was 14 cm(3) and the mean relative increase Vol-T(1)/IMT, mean relative common Vol-T(1)/IMT, and mean relative Vol-T(1) minus IMT was 21%, 4%, and 64% of the mean composite Vol-T(1)/IMT, respectively. In 19 (29%) of 66 patients, the focal IMT uptake was located outside the MRI changes. In this subgroup, the mean residual volume defined by focal IMT uptake in MRI/IMT-SPECT images, mean Vol-T(1), and mean Vol-T(2) was 19 cm(3), 10 cm(3), and 70 cm(3), respectively. The mean relative increase T(2)/IMT was 14% and T(1)/IMT was 61%. In this subgroup, the additional information of SPECT led to an increase in boost volume (mean relative increase BV-IMT) by 20%.
CONCLUSION: In patients with surgically resected brain gliomas, the size and location of residual IMT uptake differs considerably from the abnormalities found on postoperative MRI. Because of the known high specificity of IMT uptake for tumor tissue, the findings on IMT-SPECT may significantly modify the target volumes for radiotherapy planning. This will help to focus the high irradiation dose on the tumor area and to spare normal brain tissue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377338     DOI: 10.1016/s0360-3016(02)02984-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Clinical applications of imaging biomarkers. Part 3. The neuro-oncologist's perspective.

Authors:  A Shenoy
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

Review 3.  Magnetic resonance imaging-guided radiation therapy using animal models of glioblastoma.

Authors:  Christian Vanhove; Ingeborg Goethals
Journal:  Br J Radiol       Date:  2019-01-17       Impact factor: 3.039

4.  Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme.

Authors:  Christopher J Anker; Richard V Hymas; Lisa J Hazard; Kenneth M Boucher; Randy L Jensen; Dennis C Shrieve
Journal:  J Neurooncol       Date:  2010-04-10       Impact factor: 4.130

5.  PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator.

Authors:  Julie Bolcaen; Benedicte Descamps; Tom Boterberg; Christian Vanhove; Ingeborg Goethals
Journal:  J Vis Exp       Date:  2017-12-28       Impact factor: 1.355

6.  Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Nadja Sell; Andrea Schaefer; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-18       Impact factor: 9.236

7.  Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach.

Authors:  Branislav Jeremic; Biljana Milicic; Danica Grujicic; Aleksandar Dagovic; Jasna Aleksandrovic
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-15       Impact factor: 4.553

8.  Diagnostics of cerebral gliomas with radiolabeled amino acids.

Authors:  Karl-Josef Langen; Klaus Tatsch; Anca-Ligia Grosu; Andreas H Jacobs; Matthias Weckesser; Osama Sabri
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

Review 9.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

10.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.

Authors:  Koen Van Laere; Sarah Ceyssens; Frank Van Calenbergh; Tjibbe de Groot; Johan Menten; Patrick Flamen; Guy Bormans; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.